C-suite selling totaling $231K represents modest but notable insider divestment (~0.023% of $1.0B market cap). Monitor next earnings report for potential downward revisions or lack of catalysts that could explain profit-taking. Non-cash derivative exercises are routine, but open-market sales by CEO and CFO raise caution.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Apr 17 $20.48entry
- T+1 · 7mo ago +1.90%α +2.10% · $20.87
- T+5 · 7mo ago −4.15%α −4.71% · $19.63
- T+20 · 6mo ago +30.66%α +25.29% · $26.76
- T+60 · due 4mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
KalVista Pharmaceuticals executives Palleiko (CEO) and Piekos (CFO) sold shares worth $231K in aggregate over a 7-day window, including open-market sales totaling $231K. The transactions follow derivative exercises, which are non-cash events.
Key Financial Metrics
Key Facts
- CEO Palleiko sold $193K of stock in open-market transactions on 2026-04-17.
- CFO Piekos sold $38K of stock in open-market transactions on 2026-04-17.
- Both executives also exercised derivatives (totaling $0 value) on 2026-04-16, which are routine non-cash events.
- Total open-market selling by insiders: $231K over 7 days.
Financial Impact
$231,000 in open-market selling by C-suite executives
Risk Factors
- Insider selling may signal lack of confidence in near-term prospects
- Potential for negative market perception despite modest dollar size
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KALV-1776728476891 |
Track record
12 reports on KALV
2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +0.45% at T+20 after the Apr 29, 2026 report. 2 of 5 went positive at some point.
Filters
- Jun 22, 202621w ago 15-12G Bearish 7/10 No price data
- Jun 17, 202621w ago EFFECT Neutral 3/10 Entry $27.00 No price data
- Jun 11, 202622w ago 8-K Neutral 5/10 Entry $26.99 No price data
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $27.00 No price data
- May 19, 202625w ago Insider Cluster Bearish 5/10 Entry $26.81 to $26.79 ▲ +0.07% +1.31% vs SPY
- May 19, 202625w ago Insider Cluster Neutral 2/10 Entry $26.81 to $26.79 ▼ −0.07% −1.31% vs SPY
- Apr 29, 202628w ago 8-K Bullish 8/10 Entry $26.67 to $26.71 ▲ +0.15% −2.96% vs SPY
- Apr 17, 202630w ago Insider Cluster Bearish 6/10 Viewing Entry $20.48 to $19.63 ▲ +4.15% +4.71% vs SPY
- Feb 23, 202638w ago Insider Cluster Bearish 6/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
- Feb 23, 202638w ago Insider Cluster Bearish 7/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers